JP2026501225A - 環状ｇｍｐ－ａｍｐ合成酵素の阻害剤としてのチアジアゾール誘導体及びその使用 - Google Patents

環状ｇｍｐ－ａｍｐ合成酵素の阻害剤としてのチアジアゾール誘導体及びその使用

Info

Publication number
JP2026501225A
JP2026501225A JP2025536183A JP2025536183A JP2026501225A JP 2026501225 A JP2026501225 A JP 2026501225A JP 2025536183 A JP2025536183 A JP 2025536183A JP 2025536183 A JP2025536183 A JP 2025536183A JP 2026501225 A JP2026501225 A JP 2026501225A
Authority
JP
Japan
Prior art keywords
compound
independently
alkyl
formula
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025536183A
Other languages
English (en)
Japanese (ja)
Other versions
JP2026501225A5 (https=
Inventor
ビバリッジ，ラムジー
バーチ，ジェイソン
シブラ，ステファーヌ
シル，パトリック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ventus Therapeutics US Inc
Original Assignee
Ventus Therapeutics US Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventus Therapeutics US Inc filed Critical Ventus Therapeutics US Inc
Publication of JP2026501225A publication Critical patent/JP2026501225A/ja
Publication of JP2026501225A5 publication Critical patent/JP2026501225A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2025536183A 2022-12-20 2023-12-19 環状ｇｍｐ－ａｍｐ合成酵素の阻害剤としてのチアジアゾール誘導体及びその使用 Pending JP2026501225A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263433987P 2022-12-20 2022-12-20
US63/433,987 2022-12-20
US202363501320P 2023-05-10 2023-05-10
US63/501,320 2023-05-10
PCT/US2023/084787 WO2024137607A1 (en) 2022-12-20 2023-12-19 Thiadiazole derivatives as inhibitors of cyclic gmp-amp synthase and uses thereof

Publications (2)

Publication Number Publication Date
JP2026501225A true JP2026501225A (ja) 2026-01-14
JP2026501225A5 JP2026501225A5 (https=) 2026-01-27

Family

ID=89768384

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025536183A Pending JP2026501225A (ja) 2022-12-20 2023-12-19 環状ｇｍｐ－ａｍｐ合成酵素の阻害剤としてのチアジアゾール誘導体及びその使用

Country Status (12)

Country Link
US (1) US20240270740A1 (https=)
EP (1) EP4638446A1 (https=)
JP (1) JP2026501225A (https=)
KR (1) KR20250131845A (https=)
CN (1) CN120530109A (https=)
AU (1) AU2023408761A1 (https=)
CL (1) CL2025001819A1 (https=)
CO (1) CO2025007987A2 (https=)
IL (1) IL321525A (https=)
MX (1) MX2025007158A (https=)
TW (1) TW202434205A (https=)
WO (1) WO2024137607A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026077404A1 (zh) * 2024-10-10 2026-04-16 北京知维拓医药科技有限公司 一种杂环类化合物及其用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019055750A1 (en) * 2017-09-15 2019-03-21 Aduro Biotech, Inc. PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF
JP2019510787A (ja) * 2016-04-05 2019-04-18 イミューン センサー リミテッド ライアビリティ カンパニー ｃＧＡＳアンタゴニスト化合物
WO2021233852A1 (en) * 2020-05-20 2021-11-25 F. Hoffmann-La Roche Ag Cgas inhibiting triazolopyrimidone derivatives
WO2022137082A1 (en) * 2020-12-22 2022-06-30 Novartis Ag Pyrrolo[3,2-b]pyridine derivatives useful in treating conditions associated with cgas
WO2022137085A1 (en) * 2020-12-22 2022-06-30 Novartis Ag Indole derivatives useful in treating conditions associated with cgas
CN115160279A (zh) * 2022-07-27 2022-10-11 中国药科大学 苯并吡喃酮类化合物、药物组合物和应用
JP2024542128A (ja) * 2021-11-08 2024-11-13 ベンタス・セラピューティクス・ユー・エス・インコーポレイテッド ヘテロ環式化合物およびその使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
EP2934598B1 (en) 2012-12-19 2018-04-18 Board Of Regents, The University Of Texas System Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
BR112020016008A2 (pt) 2018-02-05 2020-12-15 The Rockefeller University Composto, método para inibir uma resposta inflamatória em um paciente, método para inibir inflamação em um paciente, método para inibir expressão de interferon ativada por dsdna em um mamífero, método para tratar metástase de câncer em um paciente e formulação farmacêutica
WO2020072492A1 (en) * 2018-10-02 2020-04-09 Baruch S. Blumberg Institute Benzamide derivatives as cgas-sting pathway agonists

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019510787A (ja) * 2016-04-05 2019-04-18 イミューン センサー リミテッド ライアビリティ カンパニー ｃＧＡＳアンタゴニスト化合物
WO2019055750A1 (en) * 2017-09-15 2019-03-21 Aduro Biotech, Inc. PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF
WO2021233852A1 (en) * 2020-05-20 2021-11-25 F. Hoffmann-La Roche Ag Cgas inhibiting triazolopyrimidone derivatives
WO2022137082A1 (en) * 2020-12-22 2022-06-30 Novartis Ag Pyrrolo[3,2-b]pyridine derivatives useful in treating conditions associated with cgas
WO2022137085A1 (en) * 2020-12-22 2022-06-30 Novartis Ag Indole derivatives useful in treating conditions associated with cgas
JP2024542128A (ja) * 2021-11-08 2024-11-13 ベンタス・セラピューティクス・ユー・エス・インコーポレイテッド ヘテロ環式化合物およびその使用
CN115160279A (zh) * 2022-07-27 2022-10-11 中国药科大学 苯并吡喃酮类化合物、药物组合物和应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LAMA, LODOE ET AL.: ""Development of human cGAS-specific small-molecule inhibitors for repression of dsDNA-triggered int", NATURE COMMUNICATIONS, vol. 10, no. 1, JPN6026004836, 21 May 2019 (2019-05-21), ISSN: 0005794252 *
ZHAO, WENFENG ET AL.: ""In Silico Screening-Based Discovery of Novel Inhibitors of Human Cyclic GMP-AMP Synthase: A Cross-", JOURNAL OF CHEMICAL INFORMATION AND MODELING, vol. 60, no. 6, JPN6026004835, 27 May 2020 (2020-05-27), pages 3265 - 3276, ISSN: 0005794251 *

Also Published As

Publication number Publication date
CN120530109A (zh) 2025-08-22
TW202434205A (zh) 2024-09-01
AU2023408761A1 (en) 2025-06-19
MX2025007158A (es) 2025-07-01
CL2025001819A1 (es) 2025-09-26
WO2024137607A1 (en) 2024-06-27
US20240270740A1 (en) 2024-08-15
KR20250131845A (ko) 2025-09-03
EP4638446A1 (en) 2025-10-29
IL321525A (en) 2025-08-01
CO2025007987A2 (es) 2025-09-08

Similar Documents

Publication Publication Date Title
TWI833104B (zh) 靶向蛋白降解化合物及其製備方法和應用
AU2016215432B2 (en) 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
CN106496210B (zh) 用作atr激酶抑制剂的化合物
TWI751163B (zh) Ｆｇｆｒ４抑制劑、其製備方法和應用
CN104557872B (zh) 稠合杂环化合物、其制备方法、药物组合物和用途
CN114929706A (zh) Kras g12c的抑制剂
KR20220012248A (ko) 퀴나졸린 화합물 및 이의 의약품에서의 응용
TW202128640A (zh) Gpr119激動劑
EP4069702A1 (en) Sstr5 antagonists
AU2005321903A1 (en) Thienopyrimidine derivatives as phosphodiesterase 10 inhibitors
JP2026501225A (ja) 環状ｇｍｐ－ａｍｐ合成酵素の阻害剤としてのチアジアゾール誘導体及びその使用
WO2024233767A1 (en) Inhibitors of cyclic gmp-amp synthase and uses thereof
EP4652164A1 (en) Inhibitors of cyclic gmp-amp synthase and uses thereof
CN116332905B (zh) (s)-n-苯基-1-(吡啶-2-基)吡咯烷-2-甲酰胺衍生物
JP7772431B2 (ja) Ｂｃｌ－２阻害薬
JP2025521507A (ja) 置換縮合二環式化合物および関連する治療方法
CN116348472B (zh) 大环化合物
WO2025240840A1 (en) Aromatic heterocycle derivatives and aromatic carbocycle derivatives having pde4d inhibitory activity
WO2025024288A1 (en) Heterocyclic pad4 inhibitors
CN121226391A (zh) 一种杂环化合物及其组合物和应用
CN120112526A (zh) 一种egfr降解剂及其制备方法和用途
EA052150B1 (ru) Новые спироциклогексановые производные, содержащие их фармацевтические композиции и их применение в качестве антиапоптотических ингибиторов
EA048485B1 (ru) Гетероциклические производные в качестве антагонистов рецептора p2x7
EA038176B1 (ru) Производные пирроло-[1,2,5]бензотиадиазепина и их применение для лечения заболевания, вызванного вирусом гепатита в

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260119

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260119

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20260119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260217

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260421